Oregon Psychedelic Institute

Fundraising Complaint Adds To Fight Over Psychedelics

Canada should be ‘world leader’ on alternative PTSD therapies, veteran says – National

ER visits surge for people using psychedelic drugs in Ontario

These patients are considering MAiD. They say Canada has made it harder to access magic mushrooms — a treatment giving them reason to live

Experts Gather At 4th Annual MGH Psychedelics Conference

Discover the Origins of a Psychedelic Drug Synthesized by a Swiss Chemist Who Claimed It ‘Found and Called Me’

How to create psychedelics’ benefits without the ‘trip’

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

$PSY Sells Out, Raising $2 Million for Psychedelic Science — PsyDAO

Dell Medical School

Where psilocybin treatment centers could be located in Colorado Springs

Ancient Egyptians Drank Psychedelic Concoctions From This 2,000-Year-Old Mug, Study Finds

FDA’s Psychedelic Reckoning

RFK Jr will cut prescription drugs and increase weed and psychedelics access

Republicans and RFK Jr. have embraced psychedelics. What could go wrong?

A growing number of Oregon cities vote to ban psilocybin

Where Current Research Stands on Psychedelics and Mental Health

I didn’t understand RFK Jr.’s appeal until I started taking ketamine

The Great American Acid Trip

Psychedelics (Minus the Trip) Could Provide Powerful Anxiety Relief

New Association Launches to Expand Patient Access to Psychedelic Medicines

Healing, spiritual purposes drive many veterans’ use of psychedelics

Ketamine’s risks are under scrutiny as experts warn a crackdown could worsen access

French study tests psychedelics in alcoholism therapy

Advisory group says Vermont is not ready to legalize psychedelic therapies

Anti-Anxiety and Hallucination-Like Effects of Psychedelics Mediated by Distinct Neural Circuits

Re-imagining The Future of Psychedelic Medicine

Can Canada’s psychedelic drug developers shake off the sector’s bad trip?

Can ‘magic’ mushrooms help one of the most painful conditions?

Psilocybin bans were on the ballot in 17 places in Oregon. They passed in all but one

The hot new college major in San Francisco? Psychedelic drugs

Eliza Dushku’s next chapter: Evangelizing for psychedelics | John L. Micek

The world’s most mysterious psychedelic is already inside your brain

Don’t Trip. Vote ‘Yes’ on Ballot Question 4.

Mass. could soon legalize natural psychedelics, but not everyone is waiting

Question 4 Mass.: Doctors, advocates endorse legalizing psychedelics

Third US State May Legalize Psychedelics

WMass mayors back psychedelic ballot question, citing mental health crisis

Here’s what experts, readers say about legalizing psychedelics in Mass.

Law & Ethics: The Psychedelics Industry & Indigenous Peoples, A PBA Four-Part Series – Psychedelic Bar Association

Australië is een proeftuin voor therapeutisch mdma-gebruik: ‘Het is niet zo eenvoudig als een pilletje geven en klaar’

Biopharma deals highlight innovative approaches to treating neurological diseases

Lykos Therapeutics Announces Appointments of Michael Mullette as Interim Chief Executive Officer and Dr. David Hough as Chief Medical Officer

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

Drug Science and University College London Collaboration: Advancing MDMA-Assisted Therapy

Push to legalize psychedelics moving into the spotlight

Psychedelics ballot question campaigns heat up ahead of November

Psychedelic plant and shroom fest returning to University of Michigan campus

A Psychedelic Debacle: 4-AcO, Microdosing, Media Panics and the Risks of Prohibition

How a Waynesville Clinic Is Using MDMA To Treat PTSD

Psychedelic‐assisted therapy for treating anxiety, depression, and existential distress in people with life‐threatening diseases – Schipper, S – 2024

Psychedelic drugs and treating mental illness

What Western medicine can learn from the ancient history of psychedelics

Colorado wants more public feedback for psychedelic therapy, so it’s delaying final fee approval to October

Psychedelics: How Question 4 could legalize the drugs for therapeutic use in Mass.

High hopes: Why psychedelics (in very small doses) could revolutionize the way we treat mental illness

Nazis, the CIA and the hunt for a psychedelic truth serum

Reducing harm with psychedelics

12 people shaping psychedelics drug development

Effort to make ‘MDMA’ available for veterans suffering from PTSD symptoms

Psychedelic Industry UK

John Krystal, MD: Exploring the Future of Ketamine and Psychedelic Treatment

Psychedelics group wants to protect Portland users of mushrooms, other drugs from cops

After the Lykos debacle, what’s next for psychedelic therapies?

Lykos Could See Five-Year Delay In Possible FDA Approval Of MDMA

Psychedelics can help the dying to deal with existential dread

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Drug Science and University College London Collaboration: Advancing MDMA-Assisted Therapy

Protected: Psychedelic drugs and treating mental illness

This study could be a game changer: issue 57

Godfather of the Psychedelic Sisterhood Microdoses at a Concert: issue 56

Celebrate Celebrities Selling Shrooms + Athlete’s Microdosing 🏋️: issue 55

Is this how to change your mind?: issue 54

1🍄= 1 year of therapy?: issue 53

You have to open this email bc it’s our birthday ;): issue 52

Grandma tries toad venom: issue 51

Proof that microdosing works!: issue 50

Animals that can make you trip 🐜: issue 49

neurodivergents evade bad trips: issue 48

Try psychedelics safely and legally at church: issue 47

Canadian Government supports psychedelic research!❤️🍄: issue 46

How YOU can make a difference in the psychedelic revolution 🚲: issue 45

Could this be the real reason why psilocybin is better than antidepressants?: issue 44

Here’s a benefit of shrooms you’ve never heard: issue 43

Study finds that people who read psychedelic newsletters are cooler and more successful than their friends: issue 42

Sustainable Psychedelics✨: issue 41

Microdosing for anxiety + psychedelic nature therapy: issue 40

Psychedelics for weight management: issue 39

The DEA is no longer banning these drugs

This study could be a game changer

First Phase 3 trial receives government funding

2 years til medical legalization!

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Creso Pharma’s wholly-owned psychedelics subsidiary,
Halucenex Life Sciences Inc. making progress ahead of
its planned Phase II clinical trials

Red Light Holland and Mistercap LLC Partnership Update

George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer

Awakn Provides a Business & Corporate Update

Small Pharma Reports Fiscal First Quarter 2023 Highlights

Zylorion Announces Filing of U.S. Provisional Patent For Novel Second-Generation Psilocybin-Based Compound

Doseology Expands into US Retail Market

Enveric Biosciences Announces Reverse Stock Split

Greenbrook TMS Announces Closing of Success TMS Acquisition and US$75 Million Credit Facility With Madryn Asset Management

Numinus Wellness Inc. Reports Q3 2022 Results

Pasithea Therapeutics Awarded a Drug Development Research Grant

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy and Research Centre

Psyched Wellness Announces July 19th, 2022 as the Official Date To Commence Pre-Orders for Calm

Red Light Holland to Head Sponsor Psy-Fi Festival in The Netherlands from September 14-18, 2022, One Of The Largest Psy-Trance Festivals In Europe

Telescope Inks Research Agreement With Standard Lithium

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Filament Health Issued Third Patent by United States Patent and Trademark Office

Filament Health Announces Closing if $2,500,080 Private Placement

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Albert Labs Appoints Two Industry Leading Director

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Pure Extracts Provides Q3 Corporate Update

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Filament Health Announces First Dosing In Groundbreaking FDA-approved Psilocin Clinical Trial

The Trip of a Lifetime

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds

Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Doseology Uplists to OTCQB Market in USA

Filament Health Announces Sixth Patent Issuance

IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Lexston closes previously announced Non-Brokered Unit Private Placement

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

An athlete’s take on microdosing

US military to study psychedelic therapy?

MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction

MindMed Announces Completion of Share Redesignation

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Heads of Agreement secured with leading pharma and healthcare products company, China Chemical & Pharmaceutical Co., Ltd. (“CCPC”) to launch Sierra Sage Herbs LLC (“SSH”) products for Taiwanese animal healthcare market

Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory

Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000

Pure Extracts Signs Listing Agreement With Shoppers Drug Mart and Receives Initial Purchase Order

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psyched Wellness announces date for their pilot production run of the first legal Amanita Muscaria tincture product, Calm

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations

LOVE Pharma Inc. Announces Second Closing Of Financing

Optimi CEO, Bill Ciprick, Sits Down With Investing News Network (INN)

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Pure Extracts Receives Purchase Order for a New Listing of High-potency Vape Carts From the Ontario Cannabis Store

Red Light Holland Update Plans to Enter Oregon Legal Psilocybin Service Market to Promote Diversity and Equity in Alignment with Measure 109 Regulations

Incannex – Director and management update

HAVN Life Enters Supply Agreement With MPB Group Inc.

Optimi Health Initiates Agreement With Sabi Mind for Therapeutic Supplies of Psilocybin, MDMA

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

Filament Health Announces Annual General Meeting Voting Results

Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

Telescope Launches First Automation Product

Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration

Greenbrook TMS Provides an Update on the Success TMS Acquisition

Lexston increases previously announced Non-Brokered Unit Private Placement

Numinus Unveils New Logo and Brand Identity

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Cybin Announces Additional Adelia Milestone Achievement

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders and Other Corporate Updates

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

Oregon county opposing psilocybin measure

Colorado to vote on psilocybin measure this Fall!

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

PharmAla Biotech Registers Trademark for MDMA

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Silo Pharma Expands License Agreement and Patent Portfolio

Tryp Therapeutics Appoints New Chief Operating Officer

Ketamine for corporate wellness

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

HAVN Life to Be Featured on Viewpoint With Dennis Quaid

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

MAVIRET® (glecaprevir/pibrentasvir) Approved by Health Canada for Pediatric Patients with Chronic Hepatitis C

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Nova Mentis to Present at the H.C. Wainwright Mental Health Conference

Numinus Applies for International Patent Filing of Psychedelics Production Process

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

Volunteer at Burning Man

What machine learning tells us about microdosing

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program

Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations

Awakn Life Sciences to Present In Upcoming June 2022 Conferences

MAPS under fire for alleged investigator misconduct

Optimi Health Requests Approval to Manufacture MDMA, Other Synthetic Psychedelics

Red Light Holland Closes Acquisition of 100 Acres of Farmland in Ontario, Canada Expanding its Mushroom Farms Division in North America